Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Enamelon (ENML) - Does anyone follow this? -- Ignore unavailable to you. Want to Upgrade?

To: Mama Bear who wrote (771)	2/11/1999 12:37:00 PM
From: Kelton	Read Replies (1) \| Respond to of 863

Last I checked, ENML is paying $400,000 / year to the ADA for the license, not $5,000, or am I wrong? But what impresses me is that in addition, their own R&D has produced 8 patents on improvements that they have made to the original formulation. #11 is by far the most impressive to me for its application outside of just toothpaste, but perhaps something that can be used in clinical dentistry. Large companies pass up on good technology all the time, it doesn't bother me that the big boys didn't grab it first. They were more concentrated on the problems with flourosis damage that their various formulations were causing to teeth, and not something that would enhance flouride. Little did they realize that this formulation is exactly what helps prevent flourosis by properly allowing the crystals in the enamel rods to take up flouride to produce the natural hydroxyapetite crystals.